We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 23, 2019

Camrelizumab in Relapsed/Refractory Classical Hodgkin's Lymphoma

Clinical Cancer Research


Additional Info

Clinical Cancer Research
A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
Clin. Cancer Res 2019 Nov 08;[EPub Ahead of Print], Y Song, J Wu, X Chen, et al

Further Reading